Solid Tumor: Newly Diagnosed

Clinical Pathways promote evidence based, safe, and high-value care for patients by providing clinical recommendations and standard processes. They are developed by multidisciplinary committees of subject matter experts, informed by methodical review of available evidence and consensus among committee members. 

Clinical Pathways:

• Newly Diagnosed Solid Tumors: Diagnostic Management Continuum Algorithm
• Newly Diagnosed Solid Tumors: Extremity Tumors Algorithm
• Newly Diagnosed Solid Tumors: Renal Tumors Algorithm
• Newly Diagnosed Solid Tumors: Suprarenal Tumors Algorithm
• Newly Diagnosed Solid Tumors: Liver Tumors Algorithm
• Newly Diagnosed Solid Tumors: Retroperitoneal Tumors Algorithm
• Newly Diagnosed Solid Tumors: Abdominal NOS Tumors Algorithm
• Newly Diagnosed Solid Tumors: Thoracic Tumors Algorithm
• Newly Diagnosed Solid Tumors: Ovarian/Uterine Tumors Algorithm
• Newly Diagnosed Solid Tumors: Testicular Tumors Algorithm
• Newly Diagnosed Solid Tumors (Diagnostic Management) Synopsis -  provides care standards employed for this clinical pathway

Inclusion and exclusion criteria:

• Inclusion:
  • Patients with suspected malignant or newly diagnosed solid tumor in an extremity, renal, suprarenal, liver, retroperitoneal, abdominal (not otherwise specified), thoracic, ovarian/uterine, and testicular locations
• Exclusion:
  • Patients with suspected anterior mediastinal mass

Committee members involved in the development:

• Joel Thompson, MD | Hematology/Oncology/BMT | Committee Chair
• Chris Halphen, DO | Orthopaedic Surgery | Committee Member
• Shahab Abdessalam, MD, FACS, FSSO | Pediatric Surgery | Committee Member
• Brenton Reading, MD | Radiology| Committee Member
• Melissa A. H. Gener, MD, FCAP | Pathology and Laboratory Medicine | Committee Member
• Ashli Lawson, MD | Gynecology | Committee Member
• Joel Koenig, MD | Urology | Committee Member
• Kris Laurence, BHS, CCRP | Hematology/Oncology/BMT | Committee Member
• Lindsey Fricke, RN, MSN, FNP-BC, CPHON | Hematology/Oncology/BMT | Committee Member

EBP Committee Members:

• Todd Glenski, MD, MSHA, FASA | Anesthesiology, Evidence Based Practice | Committee Member
• Jarrod Dusin, MS, RD, LD, CPHQ | Evidence Based Practice | Committee Member

Publication dates:

• Finalized date: 6/2026
• Next expected revision date: June 2029

If you have any questions regarding this content or identify a broken link, please email evidencebasedpractice@cmh.edu. 

These pathways do not establish a standard of care to be followed in every case. It is recognized that each case is different, and those individuals involved in providing health care are expected to use their judgment in determining what is in the best interests of the patient based on the circumstances existing at the time. It is impossible to anticipate all possible situations that may exist and to prepare a pathway for each. Accordingly, these pathways should guide care with the understanding that departures from them may be required at times.